header logo image


Page 3«..2345..»

Archive for January, 2013

Meager, Meager Coverage of Yesterday’s IOM-Stem Cell Meeting

Sunday, January 27th, 2013

The $3 billion California stem cell
agency seemed all but invisible this morning in terms of mainstream
media coverage.

Only one major outlet reported on
the watershed events yesterday at the CIRM governing board meeting at
the Claremont Hotel in Oakland – at least from what our Internet
searches show.
The piece was written by Bradley Fikes
in the San Diego U-T, the dominant daily newspaper in that area,
which is a major biotech center. The major media in the San Francisco
Bay area, home to the stem cell agency and also a biotech center, were absent from the coverage.
Fikes wrote a straight forward account
of the meeting, saying that the governing board voted “ to
accept in concept proposed
changes
 to reduce conflicts of interest on the agency's
governing committee.”
Fikes wrote the story based on the audiocast of the meeting. He probably would not have written his daily piece without the availability of the audiocast. 
Some of those connected with the stem
cell agency often wonder about the lack of mainstream coverage of its doings,
particularly the lack of favorable coverage.
Much of it has to do with the shriveled
state of the media business, which is understaffed and overworked
compared to 15 years ago. Specialized science reporters are all but
an extinct species. Also, the mainstream media has traditionally
ignored the affairs of most state agencies.
Speaking as a former editor at a major
Northern California newspaper, I would not have sent a reporter to
cover this week's two-day CIRM board meetings. It would have consumed
too much valuable time with little likelihood of a major story,
especially when weighed against other story possibilities. There was
no guarantee that the board would have even acted. The events and
their significance could be better handled in a roundup story later
with more perspective, perhaps keying on the board's meeting in
March, where details of yesterday's action will be fleshed out. The
fact is that many, very important events occur within state
government every day that never receive media attention. Some don't
even see the light of day until a catastrophe occurs.
All of this may be deplorable in the
eyes in stem cell agency backers and others, but it is the reality of
today's news business.  

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/8q4FDQb-BUk/meager-meager-coverage-of-yesterdays.html

Read More...

Roll Call Vote on the Thomas Plan Dealing with IOM Recommendations

Sunday, January 27th, 2013

Here is the roll call vote yesterday on the plan to deal with the findings of the Institute of Medicine
concerning the California stem cell agency. The vote was 23-0 with
one abstention. The board has 29 seats. Not all board members were in attendance,
and it is not entirely clear whether all the board members in attendance
voted. Among other things, the plan calls for members with links to
institutions that could benefit from CIRM awards to voluntarily refrain from
voting on any applications for funding – not just those to their
institutions. The roll call was provided by a spokesman for the
agency.

Yes votes
David Brenner, dean of the UC San
Diego medical school.
Anne Marie Duliege , vice president of
Affymax
Michael Freidman, CEO City of Hope
Michael Goldberg, executive chairman of Nodality, Inc., and DNAnexus, appointed as executive officer of a commercial life science entity
Sam Hawgood, dean of the UC San
Francisco medical school
Steve Juelsgaard, former executive
vice president of Genentech, appointed as executive officer of a
commercial life science entity
Sherry Lansing, chairwoman of the UC
board of regents, appointed as patient advocate
Jacob Levin, assistant vice
chancellor, research, UC Irvine, and alternate for Sue Bryant,
interim provost at UC Irvine
Bert Lubin, CEO of Childrens Hospital,
Oakland
Robert Price, associate vice
chancellor for research, political science professor, alternate for
the UC Berkeley chancellor
Francisco Prieto, Sacramento physician
and patient advocate member of the board
Robert Quint, San Jose physician and
patient advocate member
Duane Roth, San Diego businessman,
appointed as executive officer of a commercial life science entity
Joan Samuelson, patient advocate member
Jeff Sheehy, patient advocate member
Jon Shestack, patient advocate member
Os Steward, patient advocate member and
head of the Reeve-Irvine Research Center at UC Irvine
Jonathan Thomas, chairman of the board
and Los Angeles bond financier
Art Torres, patient advocate member
Kristiina Vuori, interim CEO of
Sanford Burnham Research Institute
Diane Winokur, patient advocate member

Claire Pomeroy, dean of the UC Davis medical school
Shlomo Melmed, senior vice president for academic affairs, Cedars Sinai
Abstaining
Michael Marletta, CEO of Scripps
Research

(Editor's note: Based on information provided by CIRM, an earlier version of this item incorrectly reported that the vote was 21-0. It also contained errors on three names. All have been corrected. Thanks for the heads up on the misspellings from a board member who will remain unnamed.)

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/DYyBzk0Er5g/roll-call-vote-on-thomas-plan-dealing.html

Read More...

Reaction to IOM: California Stem Cell Directors Approve Plan on Conflicts of Interest and More

Sunday, January 27th, 2013

Directors of the $3 billion California
stem cell agency today approved a far-reaching plan aimed at resolving long-standing
conflict of interest issues involving the agency's governing board
and also at helping to maintain credibility with the public.

Jonathan Thomas
CIRM photo
The framework of the proposal by CIRM
Chairman J.T. Thomas moved forward on a 23-0 vote with one
abstention. He laid out the plan in response to sweeping recommendations from a blue-ribbon study by the Institute of Medicine. Details will be worked out and come back to the board in March. 
Acknowledging that many board members
were not pleased with the IOM criticism of the agency, Thomas said, 

“This is one of those times that we must move forward and compromise.” 

He
said issues such conflicts of interest have “stolen focus” from
the good scientific work that the agency has funded.
Thomas was reacting to the $700,000 IOM
study commissioned by CIRM governing board. The IOM recommendations
called for removing conflict
of interest problems, cleaning up a troubling dual-executive arrangement
and fundamentally changing the nature of the governing board. The IOM proposals would strip the board of its ability to approve individual grants,
greatly strengthen the role of the agency's president, significantly
alter the role of patient advocates on the governing board and engage
the biotech industry more vigorously.
Thomas' plan, which would be put in
place for up to a one-year trial period, would not do all that the
IOM wanted, but would move strongly in that direction.
State Controller John Chiang, chairman
of the only state entity with financial oversight over CIRM, endorsed
most of the proposal, said deputy controller Ruth Holton-Hodson. She
told CIRM directors that Thomas' plan was thoughtful and positive,
although Chiang did not support continued involvement of the chairman
in day-to-day operations.
The Thomas plan, which would not require legislative approval, would:
  • Have 13 members of the 29-member board
    refrain from voting on specific grant applications. The 13 would be from institutions that could benefit from CIRM grants. They would be
    allowed to participate in discussions. Thomas said this would deal
    with financial conflict of interest questions. 
  • Increase industry participation of
    industry in grant application review and step up business involvement
    internally at CIRM, including development of RFAs.
  • Redirect all scientific appeals to
    staff to evaluate for possible re-review before they go to the full
    board.
  • Move “programmatic” review of
    grants to public sessions of the full board instead of being held
    behind closed doors during grant review sessions. Patient advocate
    directors now sitting on the grant review group would no longer be
    allowed to vote during the closed-door review sessions, but they
    could participate in the discussion.

It appears, however, that the Thomas
plan would do little to deal with the dual-executive problems identified
by the IOM.

Consumer Watchdog's John M. Simpson, a
long observer of the stem cell agency, welcomed the response by
CIRM. Writing on his blog, Simpson said,

 "It looks like
the message is finally getting through to California's stem cell
agency board....
Part of what is driving the new
approach is the realization that CIRM will need to find a new source
of funding -- possibly going back to the voters -- if it is to
continue.  As Thomas told the board today, 'If we don't
have credibility, we won't have a chance of sustaining the agency.'"

During the lengthy debate this
afternoon, one director after another said they did not agree with
all that the IOM had to say, but said maintaining credibility and
trust was the key to the sustainability of the organization.
CIRM will run out of money for new
grants in less than four years. Thomas said he is working on a plan
to continue the agency's effort into the future. Details of that will
be disclosed later, he said.

(Editor's note: An earlier version of this item, based on incorrect information from CIRM, said the vote was 21-0. The correct figure is 23-0.)

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/Phybdqb0SV0/iom-california-stem-cell-directors.html

Read More...

Potential of differentiated iPS cells in cell therapy without immune rejection

Saturday, January 26th, 2013

Jan. 25, 2013 A new study from Boston University School of Medicine (BUSM) shows that tissues derived from induced pluripotent stem (iPS) cells in an experimental model were not rejected when transplanted back into genetically identical recipients. The study, published online in Cell Stem Cell, demonstrates the potential of utilizing iPS cells to develop cell types that could offer treatment for a wide range of conditions, including diabetes, liver and lung diseases, without the barrier of immune rejection.

Ashleigh Boyd, DPhil, and Neil Rodrigues, DPhil, the study's senior authors, are assistant professors of dermatology at BUSM and researchers at the Center for Regenerative Medicine (CReM) at Boston University and Boston Medical Center (BMC). They also are lead investigators at the National Institutes of Health's Center of Biomedical Research Excellence (COBRE) at Roger Williams Medical Center, a clinical and research affiliate of BUSM.

iPS cells can be developed from adult cell types, such as skin or blood, by returning them to a stem cell state using genetic manipulation. iPS cells are capable of maturing (differentiating) into all the specific cell types in the body, making them a powerful tool for biological research and a source of tissues for transplantation based therapies. Given that iPS cells can be made in a patient-specific manner, there should be great potential for them to be transplanted back into the same patient without rejection. Yet a study published in Nature in 2011 demonstrated that iPS cells transplanted in the stem cell state were rejected in genetically identical recipients.

"The Nature study provocatively suggested that tissues derived from patient-specific iPS cells may be immunogenic after transplantation. However, it never directly assessed the immunogenicity of the therapeutically relevant cell types that could be utilized in regenerative medicine and transplantation," said Rodrigues.

The BUSM researchers evaluated this matter by taking adult cells from an experimental model and deriving iPS cells from them. They then differentiated the iPS cells into three cell types: neuronal (nerve); hepatocytes (liver); and endothelial (blood vessel lining) cells. These three cell types represent each of the three germ layers present during embryonic development -- mesoderm, ectoderm and endoderm. Cells from these layers differentiate and ultimately develop into the body's tissue and organ systems. Using experiments to mirror the potential clinical use of patient-specific iPS cells in cell therapy, the team transplanted each of the differentiated cells into a genetically identical experimental model and found no signs of an elevated immune response or indications of rejection.

The study results suggest that using patient-specific iPS cells should overcome issues of immune rejection in transplantation, which will be a significant problem for potential embryonic stem cell-derived therapies. Immune rejection in transplantation is treated clinically by immunosuppressive drugs but they can have serious side-effects, including the risk of developing cancer.

"If the use of immunosuppressive drugs can be avoided, as may be the case for patient-specific iPS cell based therapies, it would be preferable. Our results are very promising and future work should be directed at assessing whether tissues derived from human iPS cells will similarly lack immunogenicity," said Boyd.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

See the article here:
Potential of differentiated iPS cells in cell therapy without immune rejection

Read More...

How to understand stem cells – 12 Hour MBA – Terrapinn Training – Video

Saturday, January 26th, 2013


How to understand stem cells - 12 Hour MBA - Terrapinn Training
http://www.12hourmba.com 12 Hour MBA in Stem Cells The 12 Hour MBA in Stem Cells is an introductory level course designed to bridge gaps in your knowledge. It is most useful to new entrants, senior managers needing a big picture refresher, professional advisors and suppliers to the industry. We make it all easy -- leading you through the dynamics of stem cells, the main business drivers, giving you precious insight into where the money is made, stem cell development, commercialisation and ethics. In less than 12 hours you #39;ll: - Understand stem cells from bench to bedside - Discover where the money is made with stem cells - Understand risk and project management techniques for stem cells - Explore practices for stem cell product commercialisation - Learn about regulations, the government and the impact they can have - Consider the ethics of stem cells - Discover what the future holds for stem cells For more information, contact us at: http://www.terrapinntraining.com/contact-us.aspx

By: TerrapinnTraining

Here is the original post:
How to understand stem cells - 12 Hour MBA - Terrapinn Training - Video

Read More...

How to understand stem cells – growth drivers – Video

Saturday, January 26th, 2013


How to understand stem cells - growth drivers
http://www.12hourmba.com 12 Hour MBA in Stem Cells The 12 Hour MBA in Stem Cells is an introductory level course designed to bridge gaps in your knowledge. It is most useful to new entrants, senior managers needing a big picture refresher, professional advisors and suppliers to the industry. We make it all easy -- leading you through the dynamics of stem cells, the main business drivers, giving you precious insight into where the money is made, stem cell development, commercialisation and ethics. In less than 12 hours you #39;ll: - Understand stem cells from bench to bedside - Discover where the money is made with stem cells - Understand risk and project management techniques for stem cells - Explore practices for stem cell product commercialisation - Learn about regulations, the government and the impact they can have - Consider the ethics of stem cells - Discover what the future holds for stem cells For more information, contact us at: http://www.terrapinntraining.com/contact-us.aspx

By: TerrapinnTraining

Read the original:
How to understand stem cells - growth drivers - Video

Read More...

How to understand stem cells – case study: Organogenesis – Video

Saturday, January 26th, 2013


How to understand stem cells - case study: Organogenesis
http://www.12hourmba.com 12 Hour MBA in Stem Cells The 12 Hour MBA in Stem Cells is an introductory level course designed to bridge gaps in your knowledge. It is most useful to new entrants, senior managers needing a big picture refresher, professional advisors and suppliers to the industry. We make it all easy -- leading you through the dynamics of stem cells, the main business drivers, giving you precious insight into where the money is made, stem cell development, commercialisation and ethics. In less than 12 hours you #39;ll: - Understand stem cells from bench to bedside - Discover where the money is made with stem cells - Understand risk and project management techniques for stem cells - Explore practices for stem cell product commercialisation - Learn about regulations, the government and the impact they can have - Consider the ethics of stem cells - Discover what the future holds for stem cells For more information, contact us at: http://www.terrapinntraining.com/contact-us.aspx

By: TerrapinnTraining

Continue reading here:
How to understand stem cells - case study: Organogenesis - Video

Read More...

How to understand stem cells – ensuring product safety – Video

Saturday, January 26th, 2013


How to understand stem cells - ensuring product safety
http://www.12hourmba.com 12 Hour MBA in Stem Cells The 12 Hour MBA in Stem Cells is an introductory level course designed to bridge gaps in your knowledge. It is most useful to new entrants, senior managers needing a big picture refresher, professional advisors and suppliers to the industry. We make it all easy -- leading you through the dynamics of stem cells, the main business drivers, giving you precious insight into where the money is made, stem cell development, commercialisation and ethics. In less than 12 hours you #39;ll: - Understand stem cells from bench to bedside - Discover where the money is made with stem cells - Understand risk and project management techniques for stem cells - Explore practices for stem cell product commercialisation - Learn about regulations, the government and the impact they can have - Consider the ethics of stem cells - Discover what the future holds for stem cells For more information, contact us at: http://www.terrapinntraining.com/contact-us.aspx

By: TerrapinnTraining

See original here:
How to understand stem cells - ensuring product safety - Video

Read More...

How to understand stem cells – ethical debate on cloning – Video

Saturday, January 26th, 2013


How to understand stem cells - ethical debate on cloning
http://www.12hourmba.com 12 Hour MBA in Stem Cells The 12 Hour MBA in Stem Cells is an introductory level course designed to bridge gaps in your knowledge. It is most useful to new entrants, senior managers needing a big picture refresher, professional advisors and suppliers to the industry. We make it all easy -- leading you through the dynamics of stem cells, the main business drivers, giving you precious insight into where the money is made, stem cell development, commercialisation and ethics. In less than 12 hours you #39;ll: - Understand stem cells from bench to bedside - Discover where the money is made with stem cells - Understand risk and project management techniques for stem cells - Explore practices for stem cell product commercialisation - Learn about regulations, the government and the impact they can have - Consider the ethics of stem cells - Discover what the future holds for stem cells For more information, contact us at: http://www.terrapinntraining.com/contact-us.aspx

By: TerrapinnTraining

Go here to read the rest:
How to understand stem cells - ethical debate on cloning - Video

Read More...

How to understand stem cells – regenerative medicine – Video

Saturday, January 26th, 2013


How to understand stem cells - regenerative medicine
http://www.12hourmba.com 12 Hour MBA in Stem Cells The 12 Hour MBA in Stem Cells is an introductory level course designed to bridge gaps in your knowledge. It is most useful to new entrants, senior managers needing a big picture refresher, professional advisors and suppliers to the industry. We make it all easy -- leading you through the dynamics of stem cells, the main business drivers, giving you precious insight into where the money is made, stem cell development, commercialisation and ethics. In less than 12 hours you #39;ll: - Understand stem cells from bench to bedside - Discover where the money is made with stem cells - Understand risk and project management techniques for stem cells - Explore practices for stem cell product commercialisation - Learn about regulations, the government and the impact they can have - Consider the ethics of stem cells - Discover what the future holds for stem cells For more information, contact us at: http://www.terrapinntraining.com/contact-us.aspx

By: TerrapinnTraining

Read the rest here:
How to understand stem cells - regenerative medicine - Video

Read More...

Thelma 9 weeks after Stem Cell Therapy – Video

Friday, January 25th, 2013


Thelma 9 weeks after Stem Cell Therapy
I created this video with the YouTube Video Editor (www.youtube.com

By: krazykp12

Continued here:
Thelma 9 weeks after Stem Cell Therapy - Video

Read More...

What are the unique properties of stem cells – Video

Friday, January 25th, 2013


What are the unique properties of stem cells
http://www.stemcellsarthritistreatment.com Stem cells differ from other cells. All stem cells mdash;regardless of their source mdash;have three general properties they are capable of dividing and renewing themselves for long periods; they are unspecialized; and they can give rise to specialized cell types. Unlike muscle cells, blood cells, or nerve cells mdash;which do not normally replicate themselves mdash;stem cells may replicate many times. A starting population of stem cells that multiplies for many months in the laboratory can yield millions of cells. If the resulting cells continue to be unspecialized, like the parent stem cells, the cells are said to be capable of long term self renewal. youtu.be

By: Nathan Wei

See the original post here:
What are the unique properties of stem cells - Video

Read More...

Stem Cells Surgery in Mexico – Video

Friday, January 25th, 2013


Stem Cells Surgery in Mexico
http://www.medicaltourismco.com The video shows a leading surgeon in stem cell surgery in Mexico. He shares his experience and expertise in handling and improving worst case scenarios with stem cell therapy. Mexico is a low cost option to patients with multiple sclerosis, chronic heart conditions, orthopedic diseases, and other progressive brain disorders. This stem cell therapist from Mexico has treated over forty patients - some of them get on with their lives two or three weeks after the surgery. The Mexican stem cell specialist has been helping people with their lives since 1978. Related Searches: Stem Cell Therapy Specialists Video Mexico, stem cell therapy for COPD Mexico Stem Cell Therapy Center Mexico, adult stem cell treatments mexico, stem cell multiple sclerosis mexico, multiple sclerosis stem cell treatment mexico, multiple sclerosis treatment mexico, multiple sclerosis cure mexico, Board-Certified stem cell Specialists mexico

By: MedicalTourismCo

More here:
Stem Cells Surgery in Mexico - Video

Read More...

Stem cells for Treatment of Erectile Dysfunction – Stem Cell ED Therapy in Bangkok – Video

Friday, January 25th, 2013


Stem cells for Treatment of Erectile Dysfunction - Stem Cell ED Therapy in Bangkok
Stem cells for the treatment of erectile dysfunction in Thailand stemcellthailand.org Proven protocol from the best regenerative doctors in Thailand. Our patients who received stem cells experienced much less difficulty related to erectile dysfunctions. Erectile Dysfunction Treatment in Bangkok is a Permanent Solution for Male Impotence and Allow Your to Regain A Powerful State. For more information please contact us.

By: stemcellthailand

See the original post:
Stem cells for Treatment of Erectile Dysfunction - Stem Cell ED Therapy in Bangkok - Video

Read More...

Transplanting Photoreceptors: The Use of Adult Retinal Stem Cells – Video

Friday, January 25th, 2013


Transplanting Photoreceptors: The Use of Adult Retinal Stem Cells
Ten years ago, Dr. Derek van der Kooy discovered stem cells in the human eye. Today, thanks to a generous donation from the Krembil Foundation, his Foundation Fighting Blindness project is developing ways to restore vision to the retina. Learn more about his research in this video. Animation produced by Tobi Lam as a Masters Research Project in Biomedical Communications at the University of Toronto.

By: FFBCanada

Read this article:
Transplanting Photoreceptors: The Use of Adult Retinal Stem Cells - Video

Read More...

Zerg DNA delivery and stem cells – Video

Friday, January 25th, 2013


Zerg DNA delivery and stem cells
Link to the Science Daily Press Release: http://www.sciencedaily.com Link to wikipedia Retroviral page: en.wikipedia.org Facebook: http://www.facebook.com Twitter: twitter.com

By: Ponera86

See the article here:
Zerg DNA delivery and stem cells - Video

Read More...

Thelma 8 weeks after Stem Cell Therapy – Video

Thursday, January 24th, 2013


Thelma 8 weeks after Stem Cell Therapy

By: krazykp12

More:
Thelma 8 weeks after Stem Cell Therapy - Video

Read More...

What are induced pluripotent (iPSC) stem cells? – Video

Wednesday, January 23rd, 2013


What are induced pluripotent (iPSC) stem cells?
As part of Dravet Syndrome Foundation #39;s educational video awareness series, Jack M. Parent, MD, of University of Michigan explains what induced pluripotent (iPSC) stem cells are and how they can be used in Dravet research. http://www.dravetfoundation.org

By: DravetFoundation

Continued here:
What are induced pluripotent (iPSC) stem cells? - Video

Read More...

Stem Cells from Blood Vessels for Bone Marrow Transplant – Video

Wednesday, January 23rd, 2013


Stem Cells from Blood Vessels for Bone Marrow Transplant
Ann Zovein, MD, studies stem cells with the goal of creating a more promising source of cells for bone marrow transplantation. The stem cells that spin off all blood types originate in the walls of blood vessels in the embryo. Zovein aims to find a way to use blood vessels as a source of stem cells that can be expanded in the lab to generate an off-the-shelf supply. http://www.ucsf.edu

By: UCSFPublicAffairs

More here:
Stem Cells from Blood Vessels for Bone Marrow Transplant - Video

Read More...

OTT: Breakfast Club Winter 2012 – Human Stem Cells 3.0: The Holy Grail of Regenerative Medicine – Video

Wednesday, January 23rd, 2013


OTT: Breakfast Club Winter 2012 - Human Stem Cells 3.0: The Holy Grail of Regenerative Medicine
Human Stem Cells 3.0: The Holy Grail of Regenerative Medicine Techid: 12022

By: EmoryUniversity

Continue reading here:
OTT: Breakfast Club Winter 2012 - Human Stem Cells 3.0: The Holy Grail of Regenerative Medicine - Video

Read More...

Page 3«..2345..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick